Severity: Warning
Message: file_get_contents(https://...@pubfacts.com&api_key=b8daa3ad693db53b1410957c26c9a51b4908&a=1): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
Filename: helpers/my_audit_helper.php
Line Number: 176
Backtrace:
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 176
Function: file_get_contents
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 250
Function: simplexml_load_file_from_url
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 3122
Function: getPubMedXML
File: /var/www/html/application/controllers/Detail.php
Line: 575
Function: pubMedSearch_Global
File: /var/www/html/application/controllers/Detail.php
Line: 489
Function: pubMedGetRelatedKeyword
File: /var/www/html/index.php
Line: 316
Function: require_once
Objectives: Radiofrequency Ablation (RFA) is a widely used technique for treatment of nasal obstruction due to inferior turbinate hypertrophy. This study aims to evaluate short and long-term outcome after RFA. Secondly, predictive factors for this outcome were evaluated.
Methods: A prospective clinical study was performed in 65 patients to evaluate short-term outcome and predictive factors (Study A). To evaluate long-term outcome and predictive factors we performed a second clinical study in 124 patients (Study B). Patients scored nasal symptoms on a 1 to 5 points visual analogue scale (VAS) and filled in questionnaires about their comorbidity, previous nasal surgery, and medication use.
Results: : There was significant short-term (6-8 weeks after RFA) improvement in nasal obstruction (VAS -1.3, < .001), trouble exercising (VAS -1.5, < .001), trouble sleeping (VAS -0.9, < .001), snoring (VAS -1.1, < .001), and hyposmia (VAS -0.6, = .004). Smoking ( = .065, = .047) was a predictor for less optimized and previous use of decongestive nasal spray ( = .135, = .005) for better short-term outcome. : Nasal obstruction significantly decreased in the long term (1-5 years after RFA) compared to VAS before RFA (VAS -1.5, < .001), but slightly increased compared to VAS 6 to 8 weeks after RFA (VAS +0.3, = .036). Allergy ( = .066, = .006), asthma ( = .068, = .005), and previous use of corticosteroid nasal spray ( = .050, = .016) were associated with a less optimized and older age ( = .217, < .001) with better long-term outcome.
Conclusion: RFA is an efficient treatment for nasal obstruction, and improves sleeping, exercising, snoring, and hyposmia. Predictors for good short-term outcome were previous use of decongestive nasal spray and no smoking. Predictors for a less optimized long-term outcome were allergy, asthma, and previous use of corticosteroid nasal spray. Older age was associated with better long-term outcome.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1177/00034894221121407 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!